Dr. Gregg A. Feinerman, MD

Dr. Feinerman practices at Barranca Surgery Center in Irvine, California.

Dr. Feinerman's NPI, 1649214826, was assigned on June 16, 2006. Dr. Feinerman graduated from George Washington University School of Medicine and Health Sciences in 1994. Dr. Feinerman holds California license A60533.

Dr. Feinerman's primary practice is Barranca Surgery Center, at 3500 Barranca Parkway, Suite #130, Irvine, CA 92606. The practice phone is (949) 552-6266.

Dr. Feinerman's primary practice is Barranca Surgery Center in Irvine, California. Dmand AI also links Dr. Feinerman to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feinerman practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Feinerman's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Feinerman is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Feinerman's licenses on file in 2 states: California and Hawaii.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and glaucoma surgery among the conditions Dr. Feinerman treats.

CMS data shows 2,633 Medicare services from Dr. Feinerman across 11 procedure codes in 2024, for 1,021 Medicare patients. Medicare paid $292,967 for them.

CMS counts 1,021 Medicare patients who saw Dr. Feinerman in 2024. The largest group is 75 to 84, with 487 patients. 75% of them have high cholesterol, and 66% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Feinerman's median patient age at 73, with 50% women.

In 2024, Dr. Feinerman wrote 2,010 Medicare Part D claims for 499 patients. 52% of them were for generic drugs. CMS names the drug for 1,915 of them, across 26 drugs with 11 or more claims each, at $182,111 in total drug cost. In 2023, CMS named 1,880 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Feinerman for performance year 2024, reported as part of a group. Dr. Feinerman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 295 procedures of cataract surgery by Dr. Feinerman, more than 89% of the clinicians it reports for that procedure.

Dmand AI links 5 papers to Dr. Feinerman, published from 2018 to 2024. 2018 was the busiest year, with 2. Dr. Feinerman's most frequent co-authors are Harvey Lee Carter, MD, James A. Davies, MD and Michael John Endl, MD.

Dmand AI links Dr. Feinerman to 2 clinical trials. Conditions studied include Cataract and Lens Diseases. Bausch & Lomb Incorporated sponsors the most, 2. Open Payments lists research payments to Dr. Feinerman that name 2 trials.

CMS Open Payments shows 249 general payments to Dr. Feinerman from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. RxSight Inc paid the most, $60,205. It also lists 10 research payments totaling $12,308 from 2017 to 2020, naming 2 clinical trials.

Dmand AI lists 3 awards for Dr. Feinerman, most recently CMS Stage 1 EHR in 2013.

Dr. Feinerman graduated from George Washington University School of Medicine and Health Sciences in 1994. Dr. Feinerman is a member of AAO and ACS.

Dr. Feinerman is in network with 14 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.